DYNAVAX TECHNOLOGIES
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018TM adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.
DYNAVAX TECHNOLOGIES
Industry:
Biopharma Biotechnology Clinical Trials Health Care Medical Device
Founded:
1996-01-01
Address:
Berkeley, California, United States
Country:
United States
Website Url:
http://www.dynavax.com
Total Employee:
501+
Status:
Active
Contact:
+1 510 848 1327
Email Addresses:
[email protected]
Total Funding:
1.04 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Universal Analytics Domain Not Resolving Apache Microsoft Exchange Online
Similar Organizations
Vero Biotech
Vero Biotech is a biopharmaceutical company that commercializes inhaled nitric oxide delivery systems for healthcare providers.
Inventiva Pharma
Inventiva is a biopharmaceutical company with several drug candidates at clinical and preclinical stage.
Aptose Biosciences
Aptose Biosciences is a biopharmaceutical company focused on the discovery, research and development of novel, first-in-class
TrioMed Innovations
TrioMed Innovations develops antimicrobial technologies and products to prevent the spreading of infections and diseases.
Vygon
Vygon offer health professionals efficient and innovative single-use medical products adapted to their needs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2009-11-10 | Symphony Dynamo | Symphony Dynamo acquired by Dynavax Technologies | N/A |
Investors List
Coalition for Epidemic Preparedness Innovations
Coalition for Epidemic Preparedness Innovations investment in Post-IPO Debt - Dynavax Technologies
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Grant - Dynavax Technologies
CRG
CRG investment in Post-IPO Debt - Dynavax Technologies
Hercules Capital
Hercules Capital investment in Debt Financing - Dynavax Technologies
National Institute of Allergy and Infectious Diseases
National Institute of Allergy and Infectious Diseases investment in Grant - Dynavax Technologies
Deerfield
Deerfield investment in Post-IPO Debt - Dynavax Technologies
Alta Partners
Alta Partners investment in Series D - Dynavax Technologies
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series D - Dynavax Technologies
Care Capital
Care Capital investment in Series D - Dynavax Technologies
Forward Ventures
Forward Ventures investment in Series D - Dynavax Technologies
Key Employee Changes
| Date | New article |
|---|---|
| 2020-09-24 | Dynavax Announces Appointment of New Board Member and Planned Retirement of Chief Financial Officer |
Official Site Inspections
http://www.dynavax.com Semrush global rank: 2.14 M Semrush visits lastest month: 9.43 K
- Host name: ec2-54-176-110-96.us-west-1.compute.amazonaws.com
- IP address: 54.176.110.96
- Location: San Jose United States
- Latitude: 37.3388
- Longitude: -121.8914
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95141
More informations about "Dynavax Technologies"
About | Core Values | Management | Board of Director - Dynavax
The Dynavax Technologies management team is comprised of industry veterans that have extensive expertise in drug discovery, development and commercialization. ... finance, investor …See details»
Investor Relations | Dynavax Technologies Corporation
Oct 8, 2024 Dynavax is a commercial-stage biopharmaceutical company built on the foundation of our significant experience and expertise in vaccine development and commercialization. …See details»
Dynavax Technologies - LinkedIn
Dynavax Technologies | 15,309 followers on LinkedIn. Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help …See details»
Dynavax Technologies Corporation - Dun & Bradstreet
Company Description: Dynavax Technologies is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative vaccines to help protect the world …See details»
Dynavax Reports Third Quarter 2021 Financial Results | Dynavax ...
Nov 4, 2021 Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® …See details»
Dynavax Appoints Ryan Spencer as Chief Executive Officer and
Dec 16, 2019 --Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer has …See details»
Dynavax Announces $100 Million Accelerated Share Repurchase …
Nov 11, 2024 Under terms of the agreement, Dynavax will pay $100 million to Goldman Sachs & Co. LLC and will initially receive approximately 6.1 million shares, with an aggregate value …See details»
Dynavax Technologies | Toll-like Receptor | Vaccines
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 Jul 23, 2024 Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine ProgramSee details»
Dynavax Reports Fourth Quarter and Full Year 2023 Financial …
Feb 22, 2024 Dynavax is developing a plague (rF1V) vaccine candidate adjuvanted with CpG 1018® currently in a Phase 2 clinical trial in collaboration with, and fully funded by, the U.S. …See details»
Contact Dynavax Technologies
Dynavax GmbH. Eichsfelder Strasse 11 D-40595 Düsseldorf Telefon: +49 211 75845 0 Fax: +49 211 75845 130. Business Development [email protected]. Investor Relations …See details»
Dynavax Reports Fourth Quarter and Full Year 2021 Financial …
Feb 28, 2022 Dynavax generated $120.5 million in cash from operations in the fourth quarter of 2021, compared to cash used in operations of $15.7 million in the fourth quarter of 2020.See details»
Dynavax and Medicago Announce Collaboration to Develop a …
Jul 8, 2020 It has been declared a pandemic by the World Health Organization (WHO). Currently there is no vaccine available for COVID-19. Dynavax Forward-Looking Statements. This press …See details»
Valneva and Dynavax Announce Collaboration to Advance Vaccine ...
Apr 22, 2020 Valneva is leveraging its technical and platform capabilities to develop an inactivated, whole virus vaccine candidate against the current coronavirus threat Dynavax is …See details»
Dynavax Technologies Corporation (DVAX) - Yahoo Finance Canada
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a …See details»
Careers at Dynavax Technologies
Dynavax is dedicated to developing and commercializing innovative vaccines to help protect the world against infectious diseases. We are a dynamic team with diverse backgrounds, and we …See details»
Dynavax Announces Grant to Scale up CpG 1018 Adjuvant …
Aug 13, 2020 --Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a grant from the Bill& …See details»
Dynavax to Present at the 7th Annual Evercore HealthCONx …
5 days ago Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today …See details»
Dynavax Technologies: What The Stock Buyback Means, What It …
Nov 13, 2024 Dynavax is poised for future growth, as evidenced by their revised revenue guidance for 2024 and their anticipation of an expanding hepatitis B vaccine market, projected …See details»
Dynavax Technologies (NASDAQ:DVAX): A Promising Biopharma …
Jun 27, 2024 Dynavax (NASDAQ:DVAX), a biopharmaceutical company, is capturing the market’s attention by developing and commercializing novel vaccines. Its flagship product, the …See details»